Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Management of Movement Disorders (Second Edition)
share announcement

Clinical Management of Movement Disorders (Second Edition)

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1943

Special Issue Editor

Dr. Lazzaro di Biase

E-Mail Website
Guest Editor
Neurology Unit, Campus Bio-Medico University Hospital Foundation, Via Álvaro del Portillo 200, 00128 Rome, Italy
Interests: Parkinson’s disease; tremor; dystonia; hyperkinetic movement disorders; ataxia; kinematic analysis; gait analysis; machine learning; adaptive therapy; telemonitoring
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

After the success of the Special Issue “Clinical Management of Movement Disorders”, this second edition aims to collect high-quality reviews, meta-analyses, and original articles with a potential impact on the clinical management of movement disorders. The Special Issue focuses on all aspects of clinical management, from relevant diagnostic techniques through to disease progression, symptom monitoring tools, and treatments. Advanced new technologies for personalized therapeutics are also welcome, along with classic overviews on phenomenology, investigative, translational, and treatment aspects.

Dr. Lazzaro di Biase
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • parkinsonism
  • tremor
  • tic
  • dystonia
  • chorea
  • athetosis
  • ballism
  • myoclonus
  • ataxia
  • diagnosis
  • symptom monitoring
  • treatments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

33 pages, 5357 KiB  
Review
Biochemical Sensors for Personalized Therapy in Parkinson’s Disease: Where We Stand
by Davide Ciarrocchi, Pasquale Maria Pecoraro, Alessandro Zompanti, Giorgio Pennazza, Marco Santonico and Lazzaro di Biase
J. Clin. Med. 2024, 13(23), 7458; https://doi.org/10.3390/jcm13237458 - 7 Dec 2024
Cited by 1 | Viewed by 1201
Abstract
Since its first introduction, levodopa has remained the cornerstone treatment for Parkinson’s disease. However, as the disease advances, the therapeutic window for levodopa narrows, leading to motor complications like fluctuations and dyskinesias. Clinicians face challenges in optimizing daily therapeutic regimens, particularly in advanced [...] Read more.
Since its first introduction, levodopa has remained the cornerstone treatment for Parkinson’s disease. However, as the disease advances, the therapeutic window for levodopa narrows, leading to motor complications like fluctuations and dyskinesias. Clinicians face challenges in optimizing daily therapeutic regimens, particularly in advanced stages, due to the lack of quantitative biomarkers for continuous motor monitoring. Biochemical sensing of levodopa offers a promising approach for real-time therapeutic feedback, potentially sustaining an optimal motor state throughout the day. These sensors vary in invasiveness, encompassing techniques like microdialysis, electrochemical non-enzymatic sensing, and enzymatic approaches. Electrochemical sensing, including wearable solutions that utilize reverse iontophoresis and microneedles, is notable for its potential in non-invasive or minimally invasive monitoring. Point-of-care devices and standard electrochemical cells demonstrate superior performance compared to wearable solutions; however, this comes at the cost of wearability. As a result, they are better suited for clinical use. The integration of nanomaterials such as carbon nanotubes, metal–organic frameworks, and graphene has significantly enhanced sensor sensitivity, selectivity, and detection performance. This framework paves the way for accurate, continuous monitoring of levodopa and its metabolites in biofluids such as sweat and interstitial fluid, aiding real-time motor performance assessment in Parkinson’s disease. This review highlights recent advancements in biochemical sensing for levodopa and catecholamine monitoring, exploring emerging technologies and their potential role in developing closed-loop therapy for Parkinson’s disease. Full article
(This article belongs to the Special Issue Clinical Management of Movement Disorders (Second Edition))
►▼ Show Figures

Figure 1

Other

Jump to: Review

7 pages, 563 KiB  
Brief Report
The Significance of High-Density Lipoprotein-Derived Inflammatory Parameters in Atypical Parkinsonisms—Pilot Study
by Piotr Alster, Bartosz Migda and Natalia Madetko-Alster
J. Clin. Med. 2025, 14(7), 2212; https://doi.org/10.3390/jcm14072212 - 24 Mar 2025
Cited by 1 | Viewed by 261
Abstract
Background/Objectives: Atypical parkinsonisms are a group of diseases with significant obstacles in the context of efficient methods of examination and understanding pathomechanisms. This is associated with the overlaps in clinical manifestation. One of the hypotheses regarding the mechanism leading to neurodegeneration in this [...] Read more.
Background/Objectives: Atypical parkinsonisms are a group of diseases with significant obstacles in the context of efficient methods of examination and understanding pathomechanisms. This is associated with the overlaps in clinical manifestation. One of the hypotheses regarding the mechanism leading to neurodegeneration in this group is related to inflammation. Methods: Authors examined 18 patients with Multiple System Atrophy—Parkinsonism Predominant (MSA-P), 15 with Progressive Supranuclear Palsy—Richardson’s Syndrome (PSP-RS) and 15 with PSP—Parkinsonism Predominant (PSP-P) (disease duration: 3–6 years) using neutrophil-to-lymphocyte-ratio, platelet-to-lymphocyte ratio and high-density lipoprotein (HDL)-derived inflammatory ratios, e.g., neutrophil to high-density lipoprotein cholesterol ratio (NHR), lymphocyte to high-density lipoprotein cholesterol ratio (LHR) and platelet to high-density lipoprotein cholesterol ratio (PHR). The potential differences between the groups were examined using one-way ANOVA, with Tukey’s HSD test. Results: The comparison revealed significant differences between PSP-RS and MSA-P in NHR (p = 0.0224). The levels of the parameters were more increased in MSA-P. No other significant differences were found. Conclusions: The possible significance of HDL in the context of brain–blood barrier permeability is a repeatedly highlighted feature of neurodegenerative diseases. The outcome of this pilot study may suggest that the evaluation of inflammatory processes should be performed with the indication of subtypes of PSP, as the character of pathomechanisms likely differs. Full article
(This article belongs to the Special Issue Clinical Management of Movement Disorders (Second Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop